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Abstract 
Background 
Tumorigenesis is characterised by changes in transcriptional control. Extensive transcript 
expression data have been acquired over the last decade and used to classify prostate cancers. 
Prostate cancer is, however, a heterogeneous multifocal cancer and this poses challenges in 
identifying robust transcript biomarkers. 
Methods 
In this study, we have undertaken a meta-analysis of publicly available transcriptomic data 
spanning datasets and technologies from the last decade and encompassing laser capture 
microdissected and macrodissected sample sets. 
Results 
We identified a 33 gene signature that can discriminate between benign tissue controls and 
localised prostate cancers irrespective of detection platform or dissection status. These genes 
were significantly overexpressed in localised prostate cancer versus benign tissue in at least 
three datasets within the Oncomine Compendium of Expression Array Data. In addition, they 
were also overexpressed in a recent exon-array dataset as well a prostate cancer RNA-seq 
dataset generated as part of the The Cancer Genomics Atlas (TCGA) initiative. Biologically, 
glycosylation was the single enriched process associated with this 33 gene signature, 
encompassing four glycosylating enzymes. We went on to evaluate the performance of this 
signature against three individual markers of prostate cancer, v-ets avian erythroblastosis 
virus E26 oncogene homolog (ERG) expression, prostate specific antigen (PSA) expression 
and androgen receptor (AR) expression in an additional independent dataset. Our signature 
had greater discriminatory power than these markers both for localised cancer and metastatic 
disease relative to benign tissue, or in the case of metastasis, also localised prostate cancer. 
Conclusion 
In conclusion, robust transcript biomarkers are present within datasets assembled over many 
years and cohorts and our study provides both examples and a strategy for refining and 
comparing datasets to obtain additional markers as more data are generated. 
Keywords 
Transcription, Prostate cancer, Signature 
Background 
Alterations in transcriptional programmes are often involved in neoplastic transformation and 
progression and defining these changes will help to understand the underlying biology of the 
malignancies. Gene Expression Microarray Analysis and more recently high-throughput 
RNA sequencing (RNA-seq) are commonly used techniques when trying to acquire an 
unbiased view of the expression levels of large numbers of genes. In order to define more 
compact and manageable expression modules that might predict risk or prognosis, various 
approaches have been used across several studies. These include the identification of 
consensus profiles across multiple datasets [1] and identifying biologically categorised gene 
sets with enriched representation of deregulated genes [2,3]. Furthermore, smaller expression 
modules have also been identified using hierarchical clustering methods to generate clusters 
containing genes with similar expression profiles across glioblastoma samples [3]. The high 
degree of prostate tissue heterogeneity, however, represents a challenge for transcriptomics 
since the relative prevalence of each cell type within a given sample determines the overall 
expression profile. This makes it difficult to compare prostate samples that have very 
different epithelial and stromal contents. Many studies have compared tumor tissue with 
benign hyperplastic tissue, or with non-tumoral prostate tissues that were not precisely 
characterised in terms of location or epithelial representation. Therefore, the outcomes of 
these analyses were possibly biased because the comparisons included tissues of diverse 
histological or embryological origins. Various approaches have been used to overcome this 
issue including in silico corrections to compensate for variable epithelial representations in 
different samples [4], and laser microdissection combined with in vitro linear amplification 
[5]. The laser capture microdissection study of Tomlins et al. yielded several informative 
molecular concepts (multi-gene modules), which provide a rich source of data for further 
refinement and follow-up as well as distinguishing between stromal and epithelial cancer 
signatures [5]. It is, however, not clear how detectable those concepts might be in material 
extracted from heterogeneous whole tissue sections, an important point given the time and 
expense associated with laser capture microdissection. 
In this study, we have therefore set out with a number of goals. First and foremost amongst 
these was to determine whether we could identify gene signatures that were statistically 
significant in datasets generated from both whole tissue sections and laser capture 
microdissected material. If so, this might indicate that with the right filtering approach, 
sample heterogeneity might not be a completely confounding challenge to transcriptomic 
analysis. Secondly, if we were able to identify such signatures, we then wanted to be able to 
refine them to a point that the signature and any pathway or process enriched within it could 
be easily validated by other experimental and clinical research groups. Here, we report a 
concise 33-gene signature with biological enrichment for glycosylation, which discriminates 
between benign tissue and prostate cancer (PCa) across multiple transcript detection 
platforms and sample types. 
Methods 
Description of datasets 
Five datasets were downloaded and used in this study. 
1. A 19-sample dataset generated by Varambally et al., using the Affymetrix Human 
Genome U133 Plus 2.0 Array platform. The dataset consisted of 13 macrodissected 
individual benign prostate, primary and metastatic PCa samples and 6 pooled samples 
from benign, primary or metastatic PCa tissues. The expression array data were 
downloaded from GEO under accession number GSE3325 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE3325). 
2. A 104-sample dataset generated by Tomlins et al., using an in-house cDNA 
microarray platform (Chinnaiyan Human 20K Hs6). Laser capture microdissection 
was used to isolate 101 specific cell populations from 44 individuals representing PCa 
progression in a range of sample categories encompassing 12 stromal and 89 
epithelial cell populations. These were subcategorised as EPI_BPH (benign prostatic 
hyperplasia epithelium), EPI_ADJ_PCA (normal epithelium adjacent to PCa), 
EPI_ATR (atrophic epithelium ? simple atrophy), EPI_ATR_PIA (atrophic 
epithelium), PIN (prostatic intraepithelial neoplasia), PCA (prostate carcinoma), 
MET_HN (Metastatic Prostate Carcinoma - Hormone Na?ve), MET_HR (Metastatic 
Prostate Carcinoma - Hormone Refractory), STROMA_EPIBPH (BPH Stroma - 
Epithelial BPH ), STROMA_NOR (Normal Stroma - Organ Donor), 
STROMA_ADJ_PCA (Normal Stroma - Adjacent to prostate cancer). In addition 
three samples were EPI_NOR (Normal Epithelium - Organ Donor). In our study we 
maintain this nomenclature in describing the dataset. The expression array data were 
downloaded from GEO under accession number GSE6099 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6099). 
3. A multi-cancer microarray dataset generated by Ramaswamy et al., and consisting of 
218 tumour samples, spanning 14 common tumour types, and 90 normal tissue 
samples and profiled on Affymetrix oligonucleotide microarrays (Hu6800 and 
Hu35KsubA GeneChips). The 14 tumour types incorporated into this study were 
breast adenocarcinoma, prostate adenocarcinoma, lung adenocarcinoma, colorectal 
adenocarcinoma, lymphoma, bladder transitional cell carcinoma, melanoma, uterine 
adenocarcinoma, leukemia, renal cell carcinoma, pancreatic adenocarcinoma, ovarian 
adenocarcinoma, pleural mesothelioma and cancers of the central nervous system. 
The dataset was downloaded from the Broad Institute website 
(http://www.broadinstitute.org/cgi-
bin/cancer/publications/pub_paper.cgi?mode=view&paper_id=61) 
4. A PCa dataset generated by Taylor et al., for 150 tumours, 29 matched normal 
samples, and 6 cell lines using the Affymetrix Human Exon 1.0 ST array platform. 
There were 27 metastatic samples amongst the 150 tumours and 35 cases of 
biochemical relapse (Additional file 1 in Taylor et al.,). The expression array data 
were downloaded from GEO under accession number GSE21034 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21034). 
5. High throughput RNA sequencing data were generated by the The Cancer Genomics 
Atlas (TCGA) consortium for 383 samples, 50 benign samples and 333 primary 
tumours. 48 of these samples represented advanced disease with Gleason grade ≥8 
and 13 cases had undergone progression as characterised by post-operative 
biochemical recurrence. Data were downloaded from the UCSC Cancer Genome 
Browser (https://genome-cancer.ucsc.edu/) - TCGA_PRAD_exp_HiSeqV2-2014-05-
02.tgz. Associated clinical data were downloaded from the TCGA Data Portal 
(https://tcga-data.nci.nih.gov/tcga/). 
6. A PCa dataset generated by Grasso et al., generated for 28 benign prostate tissue 
samples, 59 localised PCa and 35 metastatic PCa was generated on two Agilent 
microarray platforms (whole genome microarray (4x44K ,G4112F) and whole human 
genome oligo microarray (G4112A ). The expression array data were downloaded 
from GEO under accession number GSE35988 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE35988). 
7. Additional datasets were interrogated for the expression of individual genes within 
signatures through the Oncomine Compendium of Expression Array data 
(www.oncomine.org). 
Prostate cancer dependent expression changes 
To generate an initial broad progression dependent gene set, we used the prostate progression 
expression dataset GSE3325 (NCBI GEO database). We quantile normalised probe level 
intensity values and generated probe set signal estimates using RMA (1,2). We first 
characterised reporters with a coefficient of variance of less than or equal to 0.05 as 
uninformative and removed them from further analysis. Reporters having intensities below 
the 10th quantile (3.91) in more than 75% of the samples were also removed. We identified 
progression associated expression changes by linear model. Primary tumour versus benign 
and metastatic versus primary contrasts were run and differential reporters identified using a 
0.01 FDR threshold. Reporters were further filtered selecting those with a differential effect 
size of greater than or equal to 2-fold. This resulted in a progression signature set of 4662 
reporters, 3021 genes (121 primary, 2900 metastatic, primary ∩ metastatic = 102). Signatures 
derived from this primary dataset were subsequently applied to two additional datasets, one 
prostate dataset generated by Tomlins et al. [5] in a laser capture microdissection study 
(GSE6099) and another generated by Ramaswamy et al. [6] and representing multi-tissue 
primary tumours and metastases (accessible through the Broad Institute data repository: 
http://www.broadinstitute.org/cgi-bin/cancer/datasets.cgi). 
Identifying correlated gene modules 
We clustered our progression gene set using hierarchical clustering with a Ward 
agglomerative method designed to minimize intra-cluster variance (hclust, Bioconductor) and 
a 1 - Pearson correlation coefficient dissimilarity measure. We found this method produced a 
more highly correlated clustering structure when compared to other methods leading to more 
compact sub-clusters (Additional file 1). We characterised correlated gene modules by 
cutting the cluster dendrogram at branch lengths ranging from log10(0.05) to log10(3000) 
giving 39 equal intervals across the log scale. We removed clusters containing less than 3 
members from further analysis. We selected modules defined at branch lengths 0f 0.6, 0.8, 
1.1, 1.9, 2.5, 4.5, 10.6, 24.7 and 101.6 for further analysis since these gave a broad range of 
cluster numbers. Since a smaller branch length threshold does not always sub divide a parent 
module modules can be duplicated at different thresholds. These were removed from further 
analysis assigning them to the largest branch threshold at which they appears. We assigned 
Gene Ontology classifications to modules by testing for enrichment at GO nodes using a 
hyper-geometric distribution and a 0.01 p-value threshold. We carried out this analysis at the 
gene level by translating chip reporter probeset ids to Entrez gene ids. All reporters from the 
progression signature with assigned Entrez gene ids were used as background. Analysis was 
carried out using the GoStats package, Bioconductor. 
Phenotype dependent transcript module expression changes 
To determine differential regulation of modules within other expression datasets we first 
identified phenotype dependent expression changes for each sample using an absolute fold 
change filter of greater than 2. To generate fold changes against which we could filter each 
gene was scaled to a baseline intensity value. In the case of dataset GSE3325 each signal 
intensity from the primary tumour samples was scaled to the corresponding median gene 
signal intensity across the benign tumour samples. Likewise all metastatic samples were 
scaled to the median across all primary tumour samples. Prior to mapping modules to dataset 
GSE6099 we background corrected each sample using a normexp method and print tip loess 
normalised (normalizeWithinArrays(), Bioconductor). We then scaled PIN samples to 
EPI_ADJ_PCA control samples, PCA samples to PIN, MET_HNF to PCA and MET_HR to 
PCA. To identify hormone refractory dependent expression changes MET_HR samples were 
scaled to the median across the non-refractory samples MET_HN. To determine module 
induction or repression within the scaled samples we tested for enrichment of module genes 
within the sample associated expression changes using a hypergeometric distribution, <= 0.05 
fdr. Mapping was achieved across array platforms using NCBI Entrez gene ids. Modules with 
an intersection of less than 3 were discarded from the analysis. 
Phenotype segregation 
To determine if any of the enriched modules were capable of segregating samples on 
phenotype we built contingency tables across clinical conditions from each of the data sets 
(Tomlins [5] and Ramaswamy [6]) for induced and repressed modules and tested for sample 
enrichment using a Fisher?s Exact test. Here we tested each phenotypic group against all 
others from each data set. 
Cluster analysis 
To determine the best clustering method and branch length thresholds to apply to our analysis 
we clustered our 4662 reporter prostate tumour progression signature (Additional file 2: 
Table S1) using single, average, complete, Ward?s1 minimum variance method and mcquitty2 
agglomerative hierarchical clustering methods along with a divisive method. The hclust 
function from Bioconductor3 was used for the agglomerative techniques and the diana 
function from the cluster package from Bioconductor was used to run the divisive method. 
We used the cutree function at branch length thresholds ranging from 0.05 to 2 in increments 
of 0.05 to derive groups of correlated genes. In the case of the Ward agglomerative method 
where the branch scales [ it is unclear how Ward calculates its branch lengths, need to find 
out ] branch length thresholds ranged from log10(0.05) to log10(3000) in increments of 
log10(3000/0.05)/39. Branch length threshold intervals were chosen to produce a broad range 
of cluster numbers. 
Cluster correlation 
To assess the extent to which genes assigned to clusters are correlated we calculated a within-
cluster dissimilarity value for each cluster4. This is given by 
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where d xi, xj is the dissimilarity between genes i and j across all samples, i,j = 1,2,?N  where 
N is the total number of cluster members and k = 1,2,?,K  where K is the total number of 
clusters. In our case the dissimilarity measure is 1 ? Pearson correlation coefficient between 2 
genes across all samples. W(C) dissimilarity values across the array of branch length 
thresholds can be seen plotted against cluster number in Additional file 1: Figure S1. As 
observed the Ward agglomerative method out performs all other methods producing clusters 
that are less dissimilar and therefore more highly correlated than those generated from other 
methods relative to the number of clusters produced. These results provide a justification for 
using hierarchical clustering with a ward agglomerative method to generate sets of co-
regulated genes. 
Cluster gene ontology entropy 
To quantify the information content of our clusters from a biological perceptive we assigned 
GO terms to cluster members. This was achieved by mapping GO terms via reporter entrez 
gene id assignments using the GO.db annotation package from Bioconductor. To quantify the 
GO information content of a cluster we calculated Shannon Entropy bit values given by: 
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where xi is a cluster associated GO term, p(xi) is the probability of choosing xi from all cluster 
GO terms , i = 1,2,?N  where N is the total number of unique cluster GO terms, k = 1,2,?K  
where K is the total number of clusters and b = 2. H(X) bit values for different branch length 
thresholds can be seen plotted against cluster number for the different clustering techniques 
in Additional file 3: Figure S2. As observed the Ward clustering method produces clusters 
with higher GO bit values when compared to other methods. This implies greater uncertainly 
in the GO term mappings for clusters generated by the ward method thus indicating the 
production of clusters more GO information rich when compared to other methods. This 
provides further justification for using hierarchical clustering with a ward agglomerative 
method to generate sets of co-regulated genes. 
Visualization of gene signatures through heatmaps 
For visualization, sample groups were averaged using the mean prior to high level mean and 
variance normalization using the freely available software J-Express 2012 
(http://jexpress.bioinfo.no/site/). Subsequently, both sample groups and genes were 
hierarchically clustered using complete linkage and Euclidian distance using the freely 
available software Cluster 3.0 (http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm). 
Heatmaps were produced using Java Tree View (http://jtreeview.sourceforge.net/). 
Evaluating gene signature specificity and sensitivity 
Testset: Grasso 1 Platform GPL6480 
#Title  Agilent-014850 Whole Human Genome Microarray 4x44K G4112F 
#                                            tissue: benign prostate tissue (N) 
#                                                                    12 
#                                             tissue: localised prostate cancer (T) 
#                                                                     49 
#                                           tissue: metastatic castrate resistant prostate cancer (WA) 
#                                                                      27. 
Training data: Grasso 2 Platform GPL6848 
#Title  Agilent-012391 Whole Human Genome Oligo Microarray G4112A 
#                                              tissue: benign prostate tissue (N) 
#                                                                     16 
#                                               tissue: localised prostate cancer (T) 
#                                                                     10 
# tissue: metastatic castrate resistant prostate cancer (WA) 
#                                                                     8. 
To evaluate the prediction performance 33 gene signature we analysed data from a 
microarray experiment of Grasso et al as available from GEO (GSE35988) 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE35988. 
The dataset includes measurements on two different microarray platforms GPL6480 and 
GPL6848 and includes three different tissue types (benign, localised and metastatic castrate 
resistant prostate cancer). 
We used the samples typed on platform GPL6848 as trainings data to derive the weights of 
the genes in the multi-gene signature. First, we replaced missing values using the k nearest 
neighbor algorithm as implemented in the R package impute. The gene PCA3 was not 
measured on the microarray and the gene CRISP3 was not observed in more than half of 
these samples. Thus, these two genes were excluded from the signature. We estimated the 
weights of each gene using an L2 regularized logit regression model [7] with the R package 
glmnet. 
Then we used the samples typed on platform GPL6480 as test data to evaluate the prediction 
performance of the gene-signature. Per sample we computed one score as the weighted 
average over the 31 proposed genes where the weights were defined by the independent 
training data. Finally, we computed ROC statistics and report the area under the curve (AUC) 
of the ROC curve (R package ROCR). The AUC indicates the ability of a marker to 
distinguish between two groups, where a value 0.5 is random and a value of 1 represents a 
perfect distinction between the groups. Additionally, we were looking at the AUC of specific 
genes, in particular KLK3, ERG and AR. 
Results and discussion 
In order to define our starting signatures, we selected a dataset published by Varambally et al. 
about a decade ago and consisting of a small number of whole tissue sections [8]. This 
constitutes the smallest and oldest dataset used in our meta-analysis. It was, however, 
extensively validated at both the transcript and protein level in the original study and 
therefore provides a high-degree of confidence in data quality. We chose to define our 
starting signatures using this dataset in order to assess how much information could be 
derived despite the limitations in size and age. Within these data, we firstly identified 
transcripts that were differentially expressed in localised prostate versus benign tissue or in 
metastatic disease versus localised cancer using a conventional linear model approach. This 
approach identified 121 genes differentially expressed in localised primary cancers (primary 
versus benign, 0.01 FDR) and 2900 genes associated with metastatic status (metastatic versus 
primary, 0.01 FDR), which were covered by 4662 probes in total (Additional file 2: Table 
S1). To further refine these gene lists into discrete signatures, we constructed a gene 
coexpression network using Pearson correlation coefficients and hierarchical clustering using 
the Ward agglomerative method (See methods section). 
A number of different correlation or dissimilarity metrics have been employed when 
constructing co-expression networks. To determine the correlation between the genes we 
used a Pearson correlation coefficient to construct a dissimilarity matrix across all affected 
samples in the prostate tumour progression dataset and all genes identified in the preliminary 
analysis. We then used hierarchical clustering to group the genes. There are a number of 
available agglomeration methods available each producing their own clustering structure. To 
determine the best agglomeration method to apply in constructing our expression modules, 
we clustered our prostate tumour progression signature using single, average, complete, the 
Ward [9] minimum variance method and the Mcquitty [10] agglomerative hierarchical 
clustering method along with a divisive method. The performance of these clustering 
methods by using an algorithm to determine the extent to which genes assigned to clusters are 
correlated generating a within-cluster dissimilarity value for each cluster (Methods section ? 
?Cluster Correlation?). In addition, we assessed the information content in gene ontology 
terms associated with clusters generated using each method by calculating Shannon Entropy 
bit values (Methods section - ?Cluster Gene Ontology Entropy?).Shannon entropy and 
coefficient of variation are well known in a great many application domains, from theoretical 
physics to computational chemistry to materials science. They have been applied in 
bioinformatics as well, most notably in statistical genetics and molecular biology. Shannon 
entropy is derived from information theory [11]. Most relevant for this study the approach 
has previously been used as a measure of the robustness of gene regulatory networks [12],to 
accelerate feature elimination when classifying microarray expression data [13]. By these 
measures the Ward clustering method provided both more tightly associated coexpressed 
gene clusters as well as clusters with higher GO bit values when compared to other methods, 
indicative of greater information content in the ontologies derived for coexpression clusters 
generated using the Ward approach than using the other approaches. Additional file 4: Table 
S2 provides a complete list of coexpressed genes signatures generated used the Ward 
approach at all branching thresholds. 
Four large gene signatures were generated at the least stringent cut-point consisting of 1334 
genes referred to as signature 1 (annotated as 101.6.1: Additional file 5: Table S3), 652 genes 
referred to as signature 2 (annotated as 101.6.2: Additional file 6: Table S4), 836 genes 
referred to as signature 3 (annotated as 101.6.3: Additional file 7: Table S5) and 357 genes 
referred to as signature 4 (annotated as 101.6.4: Additional file 8: Table S6). Signatures 1 and 
2 contained genes that predominantly discriminated between localised PCa and benign tissue. 
Using DAVID ontology enrichment search (http://david.abcc.ncifcrf.gov/) to determine 
whether KEGG pathways were enriched within these signatures, we identified focal 
adhesions (hsa04510: Focal adhesion, p-value 7.21x10−6) (Table 1) as the most significant 
pathway for signature 1and complement and coagulation cascades for signature 2 (hsa04610: 
Complement and coagulation cascades, p-value 0.002) (Table 2). The 38 genes associated 
with the focal adhesion annotation (p-value 7.21x10−6) in signature 1 are listed in Table 1 and 
were all significantly downregulated in metastatic samples relative to benign and localised 
PCa. Half of these genes were laminins (eg. laminin alpha subunit-4 (LAMA4)), integrins 
(eg. integrin, alpha 1 (ITGA1) and five others), thrombospondins (thrombospondins 1 and 4 
(THBS1/4), collagens, actins and myosins which may reflect the remodelling of the 
extracellular matrix and loss of stroma in particular during the transition to metastasis. The 
enrichment for complement and coagulation cascades in signature 2 (p value 0.002) included 
complement (eg. C1R, C1QA, C3) and plasma factors as well as serpin peptidase inhibitor as 
listed in Table 2 and were also predominantly downregulated in metastatic cases versus 
benign tissue and localised PCa. Collectively, these pathway enrichments might reflect a 
combination of extracellular matrix changes and the contribution of infiltrating immune cells 
and the inflammatory response. However, given that the Varambally dataset consists of 
whole-tissue sections it is not possible in this meta-analysis to precisely attribute these 
signatures to a particular biological process. 
Table 1 KEGG pathway enrichment analysis for the genes comprising signature 1 (101.6.1) 
Category Term Count % PValue Genes List 
Total 
Pop 
Hits 
Pop 
Total 
Fold 
Enrichment 
Bonferroni Benjamini FDR 
KEGG_PATHWAY hsa04610:Complement and 
coagulation cascades 
10 1.56 0 C1QA, FGG, A2M, C3, KLKB1, CD46, C1R, 
SERPING1, C1S, CFD 
219 69 5085 3.37 0.33 0.33 2.97 
KEGG_PATHWAY hsa04540:Gap junction 10 1.56 0.01 TJP1, ADCY2, GNAI1, PDGFA, TUBB6, 
GUCY1A3, GJA1, LPAR1, PRKACB, ITPR2 
219 89 5085 2.61 0.88 0.65 14.98 
KEGG_PATHWAY hsa04142:Lysosome 11 1.72 0.03 AGA, HGSNAT, LAMP2, CTSK, GM2A, PSAP, 
LGMN, CTSB, SCARB2, FUCA1, CLN5 
219 117 5085 2.18 0.99 0.77 28.69 
KEGG_PATHWAY hsa04270:Vascular smooth 
muscle contraction 
10 1.56 0.05 PLA2G4A, ADCY2, CALD1, MRVI1, GUCY1A3, 
PRKCH, PRKACB, PPP1CB, MYLK, ITPR2 
219 112 5085 2.07 1 0.87 46.04 
KEGG_PATHWAY hsa04310:Wnt signaling 
pathway 
12 1.88 0.06 CCND1, PRICKLE1, CCND2, BTRC, NFAT5, 
CAMK2D, TP53, MAPK10, PRKACB, FZD5, 
FZD4, FZD7 
219 151 5085 1.85 1 0.85 51.51 
KEGG_PATHWAY hsa05330:Allograft rejection 5 0.78 0.07 HLA-DRB5, HLA-DPB1, HLA-E, HLA-DOA, 
HLA-DRA 
219 36 5085 3.22 1 0.84 56.25 
KEGG_PATHWAY hsa05416:Viral myocarditis 7 1.1 0.08 CAV1, CCND1, HLA-DRB5, HLA-DPB1, HLA-E, 
HLA-DOA, HLA-DRA 
219 71 5085 2.29 1 0.86 64.57 
KEGG_PATHWAY hsa05332:Graft-versus-host 
disease 
5 0.78 0.08 HLA-DRB5, HLA-DPB1, HLA-E, HLA-DOA, 
HLA-DRA 
219 39 5085 2.98 1 0.82 65.24 
KEGG_PATHWAY hsa04510:Focal adhesion 14 2.19 0.09 CAV1, PDGFA, MAPK10, FLNC, PPP1CB, VCL, 
CCND1, CCND2, ITGAV, COL6A2, RAP1A, 
THBS1, PIK3R1, MYLK 
219 201 5085 1.62 1 0.81 67.5 
Genes comprising signature 1 (Additional file 5: Table S3) were uploaded into the DAVID gene ontology search engine (http://david.abcc.ncifcrf.gov/). KEGG pathway enrichment was 
generated and the table represents the output file ranked based on significance and annotated by column header. 
Table 2 KEGG pathway enrichment analysis for the genes comprising signature 2 (101.6.2) 
Category Term Count % PValue Genes List Total Pop Hits Pop Total Fold Enrichment Bonferroni Benjamini FDR 
KEGG_PATHWAY hsa04110:Cell cycle 36 0.47 9.03E-20 E2F1, E2F2, E2F3, TTK, CHEK1, PTTG1, 
CCNE2, CCNE1, CDKN2A, MCM7, 
CDKN2C, CDKN2D, ORC6L, TFDP2, BUB1, 
CCNA2, STAG1, CDC7, CDC6, RBL1, SKP2, 
ESPL1, CDC20, MCM2, CDC25C, MCM4, 
CDC25A, CDC25B, CDKN1C, CCNB1, 
CCNB2, MAD2L1, PLK1, GSK3B, BUB1B, 
MAD2L2 
225 125 5085 6.51 1.29E-17 1.29E-17 1.07E-
16 
KEGG_PATHWAY hsa03030:DNA 
replication 
12 0.16 2.15E-07 RFC5, PRIM1, MCM7, RFC4, POLE2, LIG1, 
POLA1, POLA2, MCM2, RNASEH2A, 
MCM4, FEN1 
225 36 5085 7.53 3.08E-05 1.54E-05 2.55E-
04 
KEGG_PATHWAY hsa04114:Oocyte 
meiosis 
18 0.23 4.82E-06 SGOL1, AURKA, CDC20, ESPL1, PTTG1, 
CDC25C, CCNE2, CCNB1, CCNE1, CCNB2, 
MAD2L1, ADCY9, CALML3, PLK1, BUB1, 
FBXO5, CAMK2B, MAD2L2 
225 110 5085 3.7 6.89E-04 2.30E-04 0.01 
KEGG_PATHWAY hsa04914:Progesterone-
mediated oocyte 
maturation 
14 0.18 8.26E-05 HSP90AA1, CDC25C, CDC25A, CDC25B, 
CCNB1, CCNB2, MAD2L1, KRAS, ADCY9, 
PLK1, BUB1, MAD2L2, PIK3R3, CCNA2 
225 86 5085 3.68 0.01 0 0.1 
KEGG_PATHWAY hsa04115:p53 signaling 
pathway 
10 0.13 0 CCNE2, CCNB1, CCNE1, CDKN2A, CCNB2, 
RRM2, TSC2, CHEK1, PMAIP1, GTSE1 
225 68 5085 3.32 0.32 0.07 3.16 
KEGG_PATHWAY hsa05222:Small cell 
lung cancer 
11 0.14 0 E2F1, CCNE2, E2F2, CCNE1, CKS1B, E2F3, 
PTK2, SKP2, PIAS2, PIK3R3, ITGA2B 
225 84 5085 2.96 0.4 0.08 4.12 
KEGG_PATHWAY hsa04360:Axon 
guidance 
14 0.18 0 PLXNA1, EFNB3, PLXNA2, DPYSL5, 
EPHB1, PTK2, KRAS, UNC5B, PAK2, 
UNC5A, FYN, GSK3B, SRGAP1, SRGAP2 
225 129 5085 2.45 0.45 0.08 4.83 
KEGG_PATHWAY hsa00240:Pyrimidine 
metabolism 
11 0.14 0.01 PRIM1, TYMS, POLR3K, POLE2, RRM2, 
RRM1, DCK, POLA1, POLA2, NME7, TK1 
225 95 5085 2.62 0.71 0.14 9.63 
KEGG_PATHWAY hsa05219:Bladder 
cancer 
7 0.09 0.01 E2F1, RPS6KA5, E2F2, E2F3, CDKN2A, 
KRAS, PGF 
225 42 5085 3.77 0.74 0.14 10.67 
KEGG_PATHWAY hsa05215:Prostate 
cancer 
10 0.13 0.02 E2F1, CCNE2, E2F2, CCNE1, E2F3, 
HSP90AA1, KRAS, GSK3B, PIK3R3, 
CTNNB1 
225 89 5085 2.54 0.9 0.2 17.14 
KEGG_PATHWAY hsa00230:Purine 
metabolism 
14 0.18 0.02 POLR3K, POLA1, DCK, POLA2, HPRT1, 
GMPS, NME7, GART, PRIM1, ADCY9, 
POLE2, RRM2, PKLR, RRM1 
225 153 5085 2.07 0.91 0.2 18.08 
KEGG_PATHWAY hsa03410:Base excision 
repair 
6 0.08 0.02 POLE2, UNG, LIG1, MBD4, NTHL1, FEN1 225 35 5085 3.87 0.92 0.19 18.86 
KEGG_PATHWAY hsa05214:Glioma 8 0.1 0.02 E2F1, E2F2, E2F3, CDKN2A, KRAS, 
CALML3, CAMK2B, PIK3R3 
225 63 5085 2.87 0.94 0.2 21.16 
KEGG_PATHWAY hsa05200:Pathways in 
cancer 
23 0.3 0.03 E2F1, E2F2, FZD8, CKS1B, MSH6, E2F3, 
HSP90AA1, PGF, FGF9, SKP2, BIRC5, FZD2, 
CTNNB1, CTNNA2, CCNE2, CCNE1, PTK2, 
CDKN2A, KRAS, GSK3B, PIAS2, PIK3R3, 
ITGA2B 
225 328 5085 1.58 0.99 0.27 30.48 
KEGG_PATHWAY hsa00670:One carbon 
pool by folate 
4 0.05 0.03 TYMS, MTHFD2, SHMT2, GART 225 16 5085 5.65 0.99 0.26 31.03 
KEGG_PATHWAY hsa04916:Melanogenesis 9 0.12 0.07 FZD8, KRAS, ADCY9, CALML3, GSK3B, 
GNAS, CAMK2B, FZD2, CTNNB1 
225 99 5085 2.05 1 0.47 57.19 
KEGG_PATHWAY hsa05210:Colorectal 
cancer 
8 0.1 0.08 FZD8, MSH6, KRAS, GSK3B, BIRC5, FZD2, 
PIK3R3, CTNNB1 
225 84 5085 2.15 1 0.48 60.57 
KEGG_PATHWAY hsa03430:Mismatch 
repair 
4 0.05 0.08 RFC5, MSH6, RFC4, LIG1 225 23 5085 3.93 1 0.48 61.82 
KEGG_PATHWAY hsa05223:Non-small cell 
lung cancer 
6 0.08 0.09 E2F1, E2F2, E2F3, CDKN2A, KRAS, PIK3R3 225 54 5085 2.51 1 0.5 66.23 
KEGG_PATHWAY hsa05218:Melanoma 7 0.09 0.09 E2F1, E2F2, E2F3, CDKN2A, KRAS, FGF9, 
PIK3R3 
225 71 5085 2.23 1 0.5 67.79 
KEGG_PATHWAY hsa05212:Pancreatic 
cancer 
7 0.09 0.1 E2F1, E2F2, E2F3, CDKN2A, KRAS, PGF, 
PIK3R3 
225 72 5085 2.2 1 0.5 69.77 
Genes comprising signature 2 (Additional file 6: Table S4) were uploaded into the DAVID gene ontology search engine (http://david.abcc.ncifcrf.gov/). KEGG pathway enrichment was generated and the table 
represents the output file ranked based on significance and annotated by column header. 
By contrast, signatures 3 and 4 contained genes that predominantly discriminated between 
metastatic cases and benign tissue samples. The dominant pathway for signature 3 was cell 
cycle regulation (hsa04110: Cell cycle, p-value 9x10−20) and the enrichment arose from the 
overexpression of a total of 36 genes linked to this process in the metastatic cases versus 
benign tissue. The genes are listed in Table 3 and included E2F transcription factors, DNA 
replication licensing factors, cyclin-dependent kinase inhibitors, cell division cycle genes and 
components of the mitotic spindle checkpoint control apparatus. Many of these overexpressed 
genes also constitute a prognostic cell cycle progression gene signature, which has been 
validated at the transcript level in biopsy samples [14]). For signature 4, steroid biosynthesis 
was the most enriched pathway (hsa00100: Steroid biosynthesis, p-value 0.03 ? squalene 
epoxidase (SQLE), farnesyl-diphosphate farnesyltransferase 1 (FDFT1), sterol-C4-methyl 
oxidase-like gene (SC4MOL). In this case the enrichment was due to the differential 
expression of three genes that are functionally tightly linked in some cases on consecutive 
steps in the cholesterol biosynthesis pathway. FDFT1 was overexpressed, SC4MOL was 
downregulated and SQLE showed a switch in expression in which one probe on the array was 
repressed and another was overexpressed (Table 4). Downregulation occured predominantly 
in localized PCa relative to benign tissue and expression seemed higher in metastatic cases 
than localized prostate cancers. . FDFT1 overexpression, and increases in the expression of 
one probe for SQLE, were most significant in the metastatic cases compared to benign tissue 
and localised disease. These are enzymes associated with cholesterol biosynthesis in 
particular and collectively catalyse 3 out of 4 consecutive reactions in the conversion of 
farnesyl pyrophosphate to lathosterol via squalene. FDFT1 catalyses the production of 
squalene from farnesyl pyrophosphate, SQLE catalyses the conversion of squalene to 2,3-
epoxysqualene and SC4MOL catalyses the conversion of lanosterin to lathosterol. The two 
metabolites consecutively further downstream in the pathway are dehydrocholesterol and 
cholesterol. FDFT1 overexpression has previously been associated with aggressive PCa [15]). 
This is particularly intriguing since metastatic PCa is characterised by increases in the 
proliferative index of tumours [16] and the ability to produce autocrine steroid hormones 
from cholesterol in order to maintain androgen receptor activity [17]. Consequently the 
observation of increased levels of these enzymes in metastatic cases may hypothetically 
imply enhanced cholesterol biosynthesis to sustain its use for steroid hormone biogenesis by 
the tumours. 
Table 3 KEGG pathway enrichment analysis for the genes comprising signature 3 (101.6.3) 
Category Term Count % PValue Genes List Total Pop Hits Pop Total Fold 
Enrichment 
Bonferroni Benjamini FDR 
KEGG_PATHWAY hsa04110:Cell cycle 36 0.47 9.03E-20 E2F1, E2F2, E2F3, TTK, CHEK1, 
PTTG1, CCNE2, CCNE1, CDKN2A, 
MCM7, CDKN2C, CDKN2D, ORC6L, 
TFDP2, BUB1, CCNA2, STAG1, 
CDC7, CDC6, RBL1, SKP2, ESPL1, 
CDC20, MCM2, CDC25C, MCM4, 
CDC25A, CDC25B, CDKN1C, 
CCNB1, CCNB2, MAD2L1, PLK1, 
GSK3B, BUB1B, MAD2L2 
225 125 5085 6.51 1.29E-17 1.29E-17 1.07E-
16 
KEGG_PATHWAY hsa03030:DNA 
replication 
12 0.16 2.15E-07 RFC5, PRIM1, MCM7, RFC4, POLE2, 
LIG1, POLA1, POLA2, MCM2, 
RNASEH2A, MCM4, FEN1 
225 36 5085 7.53 3.08E-05 1.54E-05 2.55E-
04 
KEGG_PATHWAY hsa04114:Oocyte 
meiosis 
18 0.23 4.82E-06 SGOL1, AURKA, CDC20, ESPL1, 
PTTG1, CDC25C, CCNE2, CCNB1, 
CCNE1, CCNB2, MAD2L1, ADCY9, 
CALML3, PLK1, BUB1, FBXO5, 
CAMK2B, MAD2L2 
225 110 5085 3.7 6.89E-04 2.30E-04 0.01 
KEGG_PATHWAY hsa04914:Progesterone-
mediated oocyte 
maturation 
14 0.18 8.26E-05 HSP90AA1, CDC25C, CDC25A, 
CDC25B, CCNB1, CCNB2, MAD2L1, 
KRAS, ADCY9, PLK1, BUB1, 
MAD2L2, PIK3R3, CCNA2 
225 86 5085 3.68 0.01 0 0.1 
KEGG_PATHWAY hsa04115:p53 signaling 
pathway 
10 0.13 0 CCNE2, CCNB1, CCNE1, CDKN2A, 
CCNB2, RRM2, TSC2, CHEK1, 
PMAIP1, GTSE1 
225 68 5085 3.32 0.32 0.07 3.16 
KEGG_PATHWAY hsa05222:Small cell 
lung cancer 
11 0.14 0 E2F1, CCNE2, E2F2, CCNE1, CKS1B, 
E2F3, PTK2, SKP2, PIAS2, PIK3R3, 
ITGA2B 
225 84 5085 2.96 0.4 0.08 4.12 
KEGG_PATHWAY hsa04360:Axon 
guidance 
14 0.18 0 PLXNA1, EFNB3, PLXNA2, 
DPYSL5, EPHB1, PTK2, KRAS, 
UNC5B, PAK2, UNC5A, FYN, 
GSK3B, SRGAP1, SRGAP2 
225 129 5085 2.45 0.45 0.08 4.83 
KEGG_PATHWAY hsa00240:Pyrimidine 
metabolism 
11 0.14 0.01 PRIM1, TYMS, POLR3K, POLE2, 
RRM2, RRM1, DCK, POLA1, POLA2, 
NME7, TK1 
225 95 5085 2.62 0.71 0.14 9.63 
KEGG_PATHWAY hsa05219:Bladder 
cancer 
7 0.09 0.01 E2F1, RPS6KA5, E2F2, E2F3, 
CDKN2A, KRAS, PGF 
225 42 5085 3.77 0.74 0.14 10.67 
KEGG_PATHWAY hsa05215:Prostate 
cancer 
10 0.13 0.02 E2F1, CCNE2, E2F2, CCNE1, E2F3, 
HSP90AA1, KRAS, GSK3B, PIK3R3, 
CTNNB1 
225 89 5085 2.54 0.9 0.2 17.14 
KEGG_PATHWAY hsa00230:Purine 
metabolism 
14 0.18 0.02 POLR3K, POLA1, DCK, POLA2, 
HPRT1, GMPS, NME7, GART, 
PRIM1, ADCY9, POLE2, RRM2, 
PKLR, RRM1 
225 153 5085 2.07 0.91 0.2 18.08 
KEGG_PATHWAY hsa03410:Base excision 
repair 
6 0.08 0.02 POLE2, UNG, LIG1, MBD4, NTHL1, 
FEN1 
225 35 5085 3.87 0.92 0.19 18.86 
KEGG_PATHWAY hsa05214:Glioma 8 0.1 0.02 E2F1, E2F2, E2F3, CDKN2A, KRAS, 
CALML3, CAMK2B, PIK3R3 
225 63 5085 2.87 0.94 0.2 21.16 
KEGG_PATHWAY hsa05200:Pathways in 
cancer 
23 0.3 0.03 E2F1, E2F2, FZD8, CKS1B, MSH6, 
E2F3, HSP90AA1, PGF, FGF9, SKP2, 
BIRC5, FZD2, CTNNB1, CTNNA2, 
CCNE2, CCNE1, PTK2, CDKN2A, 
KRAS, GSK3B, PIAS2, PIK3R3, 
ITGA2B 
225 328 5085 1.58 0.99 0.27 30.48 
KEGG_PATHWAY hsa00670:One carbon 
pool by folate 
4 0.05 0.03 TYMS, MTHFD2, SHMT2, GART 225 16 5085 5.65 0.99 0.26 31.03 
KEGG_PATHWAY hsa04916:Melanogenesis 9 0.12 0.07 FZD8, KRAS, ADCY9, CALML3, 
GSK3B, GNAS, CAMK2B, FZD2, 
CTNNB1 
225 99 5085 2.05 1 0.47 57.19 
KEGG_PATHWAY hsa05210:Colorectal 
cancer 
8 0.1 0.08 FZD8, MSH6, KRAS, GSK3B, BIRC5, 
FZD2, PIK3R3, CTNNB1 
225 84 5085 2.15 1 0.48 60.57 
KEGG_PATHWAY hsa03430:Mismatch 
repair 
4 0.05 0.08 RFC5, MSH6, RFC4, LIG1 225 23 5085 3.93 1 0.48 61.82 
KEGG_PATHWAY hsa05223:Non-small cell 
lung cancer 
6 0.08 0.09 E2F1, E2F2, E2F3, CDKN2A, KRAS, 
PIK3R3 
225 54 5085 2.51 1 0.5 66.23 
KEGG_PATHWAY hsa05218:Melanoma 7 0.09 0.09 E2F1, E2F2, E2F3, CDKN2A, KRAS, 
FGF9, PIK3R3 
225 71 5085 2.23 1 0.5 67.79 
KEGG_PATHWAY hsa05212:Pancreatic 
cancer 
7 0.09 0.1 E2F1, E2F2, E2F3, CDKN2A, KRAS, 
PGF, PIK3R3 
225 72 5085 2.2 1 0.5 69.77 
Genes comprising signature 3 (Additional file 7: Table S5) were uploaded into the DAVID gene ontology search engine (http://david.abcc.ncifcrf.gov/). KEGG pathway enrichment was 
generated and the table represents the output file ranked based on significance and annotated by column header. 
Table 4 KEGG pathway enrichment analysis for the genes comprising signature 3 (101.6.4) 
Category Term Count % PValue Genes List 
Total 
Pop 
Hits 
Pop 
Total 
Fold 
Enrichment 
Bonferroni Benjamini FDR 
KEGG_PATHWAY hsa00100:Steroid 
biosynthesis 
3 0.1 0.03 SQLE, FDFT1, SC4MOL 86 17 5085 10.43 0.97 0.97 30.81 
KEGG_PATHWAY hsa05200:Pathways in 
cancer 
11 0.38 0.05 LAMA1, HRAS, PTK2, SOS1, CBL, 
VEGFA, PPARG, RALA, LEF1, 
MDM2, LAMB1 
86 328 5085 1.98 0.99 0.93 41.08 
KEGG_PATHWAY hsa04510:Focal adhesion 8 0.27 0.05 LAMA1, HRAS, PTK2, FLT1, 
DIAPH1, SOS1, VEGFA, LAMB1 
86 201 5085 2.35 1 0.85 44.04 
KEGG_PATHWAY hsa00330:Arginine and 
proline metabolism 
4 0.14 0.06 ARG1, P4HA2, P4HA1, CPS1 86 53 5085 4.46 1 0.82 49.31 
KEGG_PATHWAY hsa05216:Thyroid cancer 3 0.1 0.08 HRAS, PPARG, LEF1 86 29 5085 6.12 1 0.86 63 
Genes comprising signature 4 (Additional file 8: Table S6) were uploaded into the DAVID gene ontology search engine (http://david.abcc.ncifcrf.gov/). KEGG pathway 
enrichment was generated and the table represents the output file ranked based on significance and annotated by column header. 
Discrimination between cancer and benign control tissue and also between metastatic disease 
and other clinical cases represents an important goal of biomarker research. Thus, we used 
these gene signatures to classify clinical samples in prostate cancer samples and metastatic 
tissue samples in two additional datasets. One consisted of prostate cancer samples isolated 
by laser capture microdissection generated by Tomlins et al. [5] and the other contained 
expression array data from primary and metastatic tumours from multiple tissue sites 
generated by Ramaswamy et al. [6]. 
The Tomlins dataset consisted of various refined subgroups based on isolation of cell sub-
populations including stromal fractions, epithelial fractions, localised prostate cancer and 
hormone-na?ve and refractory metastatic disease. The Ramaswamy et al. dataset consisted of 
cancers from 14 organ sites with paired normal samples as well as normal tissues. In each 
dataset, we asked whether our signatures and sub-signatures could discriminate between the 
sample groups. To determine this, we first assessed the mean fold-change in the expression of 
each gene signature in each sample group in both datasets (Additional file 9: Table S7). We 
then performed a Fischer?s Exact test to identify signatures that were capable of 
discriminating between localised prostate cancer, metastatic prostate cancer and the other 
sample groups defined in all three published studies ? Varambally et al., Tomlins et al., and 
Ramaswamy et al. (refer to Materials and Methods for more detail on subgroups/sample 
types) (Additional file 10: Table S8). Gene ontologies were assigned to these statistically 
significant gene clusters and the clustering is represented in a heatmap for the classifying 
modules combining both the Tomlins and Ramaswamy sample sets (Figure 1 and Additional 
files 10 and 11: Tables S8 and S9 for gene ontology annotations). The smallest gene signature 
(dist.0.6.34) capable of subclustering localised prostate cancer from other samples in all three 
datasets consisted of 71 genes (Table 5). This small signature was a sub-component of the 
original signature 1 (101.6.1). The most significantly enriched biological process associated 
with these genes was vascular smooth muscle contraction (hsa04270: Vascular smooth 
muscle contraction, p-value 2x10−3) (Table 6). The four genes within this signature that were 
individually most significantly overexpressed in localised prostate cancers compared to 
benign tissues and metastatic cases were an oncogenic transcription factor, v-myc avian 
myelocytomatosis viral oncogene homolog (MYC), a proteoglycan capable of sequestering 
transforming growth factor beta called fibromodulin (FMOD), a mitochondrial enzyme 
associated with fatty acid metabolism called glycine N-acyltransferase-like protein 1 
(GLYATL1) and an extraneuronal monoamine transporter called solute carrier family 22 
member 3 (SLC22A3). MYC has been shown to be overexpressed in prostate cancer [18] and 
to drive tumourigenesis in a transgenic model of the disease [19]. Fibromodulin has not been 
widely studied in cancer and has not been implicated in prostate cancer. It is, however, 
known to be significantly overexpressed in chronic lymphocytic leukemia (CLL) versus 
normal B lymphocytes [20] and associated with a resistance signature to DNA damage-
induced apoptosis in CLL [21]. Furthermore, the expression of fibromodulin is known to be 
induced in leiomyoma in response to TGF-beta through Smad and MAP kinase signalling 
[22]. GLYATL1 has not been associated with cancers. SLC22A3 has been reported to be 
overexpressed in localised prostate cancer at the transcript level when compared to benign 
tissue [5]. 
  
Figure 1 Gene signatures capable of discriminating between prostate cancer subgroups 
and classify metastatic disease. Gene signatures generated using the Varambally dataset and 
found to be significant discriminators of metastatic disease and primary/localised cancers 
(Additional file 10: Table S8) when applied to the Tomlins and Rawaswamy datasets were 
used to cluster samples in these datasets in a heatmap. The gene signatures represented are 
those capable of characterising samples from at least one progression stage (Fischer?s exact < 
= 0.05). Gene signatures are rows and samples are columns. The colour coded bar at the base 
of the heatmap indicates the clinical grouping for each sample as also defined in the key. 
Metastatic hormone refractory, metastatic hormone na?ve and hormone refractory vs. na?ve 
represent prostate cancer cases from the Tomlins dataset, as do PIN (prostatic intraepithelial 
neoplasia) and primary carcinoma. The other categories (metastatic and primary) are samples 
from the Rawaswamy dataset and are metastatic and primary cancers from multiple organ 
sites, not simply the prostate gland. The blue bar graph on the right-hand side of the heatmap 
depicts the number of genes in each signature which are differentially expressed and 
contribute to the sample clustering in this analysis. For signature 1 (dist 101.6.1 and 
Additional file 5: Table S3) this is 1748 genes in total as highlighted and other bars are 
numbers of genes relative to this. The colour scale represents the mean log2 fold change for 
differential gene signatures (> = abs log2(2)). Red indicates module induction, green 
repression. Gene signatures significant in both directions are indicated in yellow generated by 
the addition of the corresponding red and green shades. Using the mean module log2 fold 
change we clustered the samples and modules using hierarchical clustering with euclidean 
distance as a measure of dissimilarity. Data points that contained both induced and repressed 
values have been excluded from the clustering. 
Table 5 A 71-gene signature capable of subclustering localised prostate cancer cases across multiple datasets 
Category Term Count % PValue Genes List 
Total 
Pop 
Hits 
Pop 
Total 
Fold 
Enrichment 
Bonferroni Benjamini FDR 
KEGG_PATHWAY hsa04270:Vascular smooth muscle 
contraction 
5 6.94 0 ACTG2, MYH11, 
KCNMB1, MYLK, MYL9 
26 112 5085 8.73 0.12 0.12 1.99 
KEGG_PATHWAY hsa05414:Dilated cardiomyopathy 4 5.56 0.01 DES, PLN, IGF1, TPM2 26 92 5085 8.5 0.47 0.27 9.6 
KEGG_PATHWAY hsa04960:Aldosterone-regulated 
sodium reabsorption 
3 4.17 0.02 IGF1, ATP1A2, IRS1 26 41 5085 14.31 0.66 0.31 15.92 
KEGG_PATHWAY hsa04310:Wnt signaling pathway 4 5.56 0.04 SFRP1, CAMK2G, 
PRICKLE2, MYC 
26 151 5085 5.18 0.91 0.45 31.53 
KEGG_PATHWAY hsa05410:Hypertrophic 
cardiomyopathy (HCM) 
3 4.17 0.06 DES, IGF1, TPM2 26 85 5085 6.9 0.99 0.57 49.28 
A 71-gene signature representing a subset of genes from signature 1 (101.6.1). Columns 1 and 2 represent Affymetrix probe identifiers and gene symbols, respectively. 
Columns 3-5 represent probe signals in benign, localised prostate cancer and metastatic samples, respectively. Column 6 (?primary.reporters) represents the differential probe 
signal between benign and localised prostate cancer cases with the associated p-values in column 7. Column 8 (?metastatic.reporters?) represents the differential probe signal 
between metastatic and localised prostate cases with the associated p-values in column 9. Subsequent columns headed dist.0.6 through to dist.101.6 represent the gene 
signature codes for coexpressed genes at diminishing significance thresholds proceeding left-to-right across the table. All 71 genes form part of the same signature at all 
stringency thresholds and consequently the numbering in these columns for all genes is the same. Subsequent columns provide the gene location and gene name including 
information on chromosome number, cytogenetic band identifier and unigene accession codes. The same table layout is used in Additional files 2, 4, 5, 6, 7 and 8: Tables S1-
S6. 
Table 6 71-gene signature capable of subclustering localised prostate cancer cases across multiple datasets 
Category Term Count % PValue Genes List 
Total 
Pop 
Hits 
Pop 
Total 
Fold 
Enrichment 
Bonferroni Benjamini FDR 
KEGG_PATHWAY hsa00512:O-Glycan biosynthesis 3 0.34 0.01 GALNTL4, GCNT1, 
ST6GALNAC1 
26 30 5085 19.56 0.43 0.43 8.95 
KEGG_PATHWAY hsa04610:Complement and 
coagulation cascades 
3 0.34 0.04 C4A, C4B, SERPINA1 26 69 5085 8.5 0.94 0.75 36.76 
KEGG_PATHWAY hsa05322:Systemic lupus 
erythematosus 
3 0.34 0.08 C4A, C4B, HLA-DMB 26 99 5085 5.93 1 0.83 58.75 
Genes were uploaded into the DAVID gene ontology search engine (http://david.abcc.ncifcrf.gov/). KEGG pathway enrichment was generated and the table represents the 
output file ranked based on significance and annotated by column header. 
The other genes within this coexpression signature were downregulated in prostate cancers 
versus benign tissue and the majority were myosins, such as myosin, heavy polypeptide 11, 
smooth muscle (MYH11), myocardin (MYOCD), and myosin, light chain 9, regulatory 
(MYL9)thus accounting for the pathway enrichment for vascular smooth muscle contraction. 
As prostate cancer progresses to more advanced stages there is a depletion of stromal cells 
from the tissue and this perhaps explains the dominant contribution from downregulated 
muscle-associated genes to the signature and also other features of pathway enrichments 
particularly of the focal adhesion classification [23]. In order to determine whether our 
signature was consistent across more recent datasets, we downloaded an exon-array dataset 
generated by Taylor et al., and also The Cancer Genome Atlas (TCGA) data recently 
generated using high-throughput transcript sequencing of prostate cancers [24] (data 
generated by the data generated by the TCGA Research Network: 
http://cancergenome.nih.gov/). MYC and GLYATL1 remain significantly overexpressed 
features (>1.3 fold) within these signatures in both datasets (Figure 2) with the vast majority 
of other gene transcripts downregulated including those enriched in the KEGG pathway 
analysis for vascular smooth muscle contraction. 
Figure 2 Differential expression of a 71-gene signature classifier in a prostate cancer 
exon-array dataset (Taylor et al.) and the TCGA RNA-seq dataset for prostate cancer 
(TCGA-PRAD). The expression values of the 71-gene signature (dist.0.6.34) capable of 
subclustering localised prostate cancer from other samples in all three interrogated datasets 
are shown in two independent datasets, A. a prostate cancer exon-array dataset (Taylor et al.) 
and B. TCGA RNA-seq dataset for prostate cancer (TCGA-PRAD) were used. Values were 
log2 normalized and the mean of the sample groups (PRIMARY TUMOUR/SOLID TISSUE 
NORMAL) is shown. 
Whilst our 71 gene signature mainly contains differentially expressed genes that are 
downregulated in cancers versus benign tissues, most prostate cancer biomarkers that are 
currently under evaluation are overexpressed transcripts and proteins in the disease state. 
Consequently, we next sought to evaluate genes that were overexpressed in localised prostate 
cancers in signatures 1-4 more thoroughly in other datasets. There were 97 annotated gene 
transcripts in total overexpressed (Table 7). We had previously performed pathway analyses 
on signatures 1-4 which included both up- and downregulated genes (Tables 1, 2, 3 and 4). 
We now repeated this solely for the 97 overexpressed genes and this yielded pathway 
enrichment for O-glycan biosynthesis (hsa00512: O-glycan biosynthesis, p-value 0.009) as 
the most significant KEGG enrichment (Table 8). 
Table 7 Overexpressed genes in localised prostate cancer versus benign tissue within the entire set of differentially expressed genes in 
the Varambally dataset (GSE3325) 
Gene/signature AUC benign-local AUC benign-metastatic AUC localized-metastatic 
KLK3 0.5204082 0.9104938 0.8707483 
ERG 0.812616 0.9326599 0.6099773 
AR 0.6581633 0.8395062 0.8435374 
31 Gene signature 0.994898 0.9938272 0.957672 
Derived from the Grasso Data    
Genes overexpressed in localised prostate cancer are ranked according to the degree of overexpression from highest to lowest within dataset 
GSE3325. Genes highlighted in bold are also overexpressed in at least three other independent prostate cancer expression array datasets hosted 
by the Oncomine compendium (http://www.oncomine.org) within the Top 1% of overexpressed gene transcripts in all cases. 
  
Table 8 KEGG pathway enrichment analysis for the entire set of overexpressed genes in localised prostate cancer versus benign tissue in the Varambally dataset 
(GSE3325) 
 id agilent_probe gene auc.benign.vs.local auc.benign.vs.met auc.local.vs.met 
1 10308 A_23_P334538 KLK3 0.668367346938776 0.512345679012346 0.583522297808012 
2 18945 A_24_P108401 KLK3 0.517006802721089 0.651234567901235 0.662131519274376 
3 24972 A_24_P344510 KLK3 0.520408163265306 0.910493827160494 0.870748299319728 
4 9045 A_23_P301414 ERG 0.780487804878049 0.832167832167832 0.578799249530957 
5 15382 A_23_P57323 ERG 0.790816326530612 0.759259259259259 0.507180650037793 
6 31809 A_24_P922378 ERG 0.812615955473098 0.932659932659933 0.609977324263039 
7 1039 A_23_P113111 AR 0.658163265306122 0.839506172839506 0.843537414965986 
8 18899 A_24_P106297 AMACR 0.952380952380952 0.771604938271605 0.606198034769463 
9 5760 A_23_P1833 B3GAT1 0.741496598639456 0.771604938271605 0.835222978080121 
10 31242 A_24_P914625 BEND4 0.82312925170068 0.583333333333333 0.689342403628118 
11 2222 A_23_P128304 BICD1 0.894557823129252 0.830246913580247 0.55026455026455 
12 31375 A_24_P916586 BICD1 0.852040816326531 0.62962962962963 0.623582766439909 
13 38999 A_32_P472968 BICD1 0.906462585034014 0.632716049382716 0.866969009826153 
14 31242 A_24_P914625 BEND4 0.82312925170068 0.583333333333333 0.689342403628118 
15 14293 A_23_P45786 COL9A2 0.714285714285714 0.521604938271605 0.574452003023432 
16 13511 A_23_P419760 CRISP3 1 0.8 0.6 
17 12893 A_23_P403466 DLX1 0.743197278911565 0.935185185185185 0.808767951625095 
18 34905 A_32_P142818 DLX1 0.985157699443414 0.956228956228956 0.647770219198791 
19 18202 A_23_P93058 DNAH5 0.836734693877551 0.62037037037037 0.616780045351474 
20 19295 A_24_P120462 DNAH5 0.706439393939394 0.516528925619835 0.650568181818182 
21 24667 A_24_P333461 DNAH5 0.74113475177305 0.59 0.542978723404255 
22 26067 A_24_P388786 DNAH5 0.870748299319728 0.503086419753086 0.714285714285714 
23 7096 A_23_P213424 ENC1 0.698979591836735 0.709876543209877 0.529100529100529 
24 29137 A_24_P69095 ENC1 0.819727891156463 0.805555555555556 0.932728647014361 
25 18033 A_23_P91081 EPCAM 0.819727891156463 0.709876543209877 0.525321239606954 
26 9045 A_23_P301414 ERG 0.780487804878049 0.832167832167832 0.578799249530957 
27 15382 A_23_P57323 ERG 0.790816326530612 0.759259259259259 0.507180650037793 
28 31809 A_24_P922378 ERG 0.812615955473098 0.932659932659933 0.609977324263039 
29 13214 A_23_P412214 RAP1GAP2 0.654761904761905 0.521604938271605 0.643990929705216 
30 31091 A_24_P911927 RAP1GAP2 0.62037037037037 0.753623188405797 0.678743961352657 
31 18139 A_23_P9232 GCNT1 0.945578231292517 0.604938271604938 0.6432350718065 
32 5181 A_23_P16523 GDF15 0.772108843537415 0.549382716049383 0.613756613756614 
33 7901 A_23_P250444 GJB1 0.86734693877551 0.62037037037037 0.628873771730915 
34 26494 A_24_P404840 GJB1 0.789115646258503 0.503086419753086 0.737717309145881 
35 11669 A_23_P370666 GLYATL1 0.857142857142857 0.558641975308642 0.806500377928949 
36 7727 A_23_P2344 HOXC6 0.883333333333333 0.863636363636364 0.533333333333333 
37 147 A_23_P101806 HPN 0.935374149659864 0.817901234567901 0.595616024187453 
38 13011 A_23_P406782 HPN 0.88265306122449 0.722222222222222 0.53817082388511 
39 6231 A_23_P203933 ITPR2 0.683673469387755 0.777777777777778 0.869992441421013 
40 9378 A_23_P310 MARCKSL1 0.892857142857143 0.953703703703704 0.699168556311413 
41 2744 A_23_P13442 MICAL2 0.502777777777778 0.638095238095238 0.642857142857143 
42 7851 A_23_P24843 MICAL2 0.821428571428571 0.820987654320988 0.522297808012094 
43 7314 A_23_P215956 MYC 0.909863945578231 0.595679012345679 0.689342403628118 
44 20716 A_24_P178011 MYC 0.530612244897959 0.87037037037037 0.835222978080121 
45 25948 A_24_P38363 MYC 0.772727272727273 0.975 0.656060606060606 
46 3126 A_23_P139327 OR51E2 0.903061224489796 0.645061728395062 0.816326530612245 
47 22188 A_24_P235756 OR51E2 0.840136054421769 0.737654320987654 0.862433862433862 
48 8971 A_23_P29816 PLA1A 0.758503401360544 0.734567901234568 0.808767951625095 
49 23649 A_24_P294408 PLA1A 0.811224489795918 0.799382716049383 0.843537414965986 
50 15416 A_23_P5778 RAB17 0.928571428571429 0.925925925925926 0.606953892668178 
51 7973 A_23_P251387 REPS2 0.884353741496599 0.509259259259259 0.764928193499622 
52 33496 A_32_P100109 REPS2 0.848639455782313 0.891975308641975 0.925925925925926 
53 6876 A_23_P211110 SIM2 0.797619047619048 0.811728395061728 0.562358276643991 
54 9061 A_23_P301886 SIM2 0.807291666666667 0.788461538461538 0.50400641025641 
55 15035 A_23_P52939 SLC43A1 0.857142857142857 0.657407407407407 0.53514739229025 
56 22855 A_24_P260443 THBS4 0.860544217687075 0.808641975308642 0.963718820861678 
57 1849 A_23_P123503 TRIB1 0.770408163265306 0.654320987654321 0.569916855631141 
58 22636 A_24_P252497 TRIB1 0.698979591836735 0.524691358024691 0.690854119425548 
59 4805 A_23_P160460 UAP1 0.841836734693878 0.657407407407407 0.854875283446712 
Genes were uploaded into the DAVID gene ontology search engine (http://david.abcc.ncifcrf.gov/). KEGG pathway enrichment was generated and the table represents the 
output file ranked based on significance and annotated by column header. 
To further refine this gene set, we then interrogated the Oncomine compendium of expression 
array data to determine which of these 97 genes are significantly overexpressed in at least 
three additional independent prostate cancer datasets when a Top 1% overexpression 
threshold was applied together with a p-value threshold of 1x10−4 [25]. Thirty three annotated 
genes, around one-third of the 97-gene set fulfilled these criteria. This included 3 of the 4 
overexpressed genes (MYC, GLYATL1 and SLC22A3) in the 71 gene signature subgrouping 
prostate cancers in the Varambally, Tomlins and Ramaswamy studies (highlighted in bold in 
Table 7). This 33 gene set also included four of the five glycosylating enzymes (UDP N-
acetylglucosamine pyrophosphorylase 1 (UAP1), glucosaminyl (N-acetyl) transferase 1, core 
2 (GCNT1), beta-1,3-glucuronyltransferase 1 (B3GAT1) and RAP1 GTPase activating 
protein 2 (RAP1GAP2/GARNL4)) contributing to the ontology enrichment for glycan 
biosynthesis in the larger 97 gene set. Notably, others and we have recently reported that 
UAP1 and GCNT1 are overexpressed in prostate cancer tissue using immunohistochemistry. 
In addition, an aminosugar conjugate, O-linked N-acetylglucosamine (O-GlcNAc), is also 
significantly elevated in prostate cancer [26,27]. Furthermore, the UAP1 transcript has also 
been reported to be detectable in urine and plasma samples as a component of a multi-gene 
signature [28]. Additionally, UDP sugar conjugates have been identified as elevated in 
prostate cancers through metabolomics and O-linked N-acetylglucosamine is an 
overexpressed prostate cancer tissue biomarker, which can be conjugated to a variety of 
proteins to affect their stability and activity including c-Myc [29,30]. Consequently, the 
presence of these genes encoding glycosylating enzymes within this signature has been partly 
validated in tissue at the proteins level and suggests that more systematic profiling of 
glycoproteins may reveal new biomarkers. 
Biologically, it is interesting to consider what might contribute to the increased expression of 
these genes in prostate cancers. Prostate cancer is driven by the dysregulated expression and 
activity of a number of transcription factors. The most notable example is the androgen 
receptor but others are overexpressed through chromosomal rearrangements and gene fusions 
as well as copy number variation as prostate cancer develops and progresses. This in turn has 
a significant impact on the expression of gene targets for these transcription factors and 
makes it plausible that a proportion of overexpressed genes reflect changes in transcription 
factor expression and activity. In this context, it is noteworthy that a total of five transcription 
factors were present in this group of 33 annotated genes ((single-minded family bHLH 
transcription factor 2(SIM2), MYC, distal-less homeobox 1 (DLX1), homeobox C6 
(HOXC6) and v-ets avian erythroblastosis virus E26 oncogene homolog (ERG)). 
c-Myc is a well-established oncogenic transcription factor, which is overexpressed through 
chromosomal amplification on 8q24 but also through post-translational events, which may 
include glycosylation of the N-terminal transactivation and concomitant antagonism of 
proteasomal degradation [31,32] [18]. ERG is part of a highly prevalent gene fusion affecting 
chromosome 21 and driven by the activity of the AR [33]. It is overexpressed in around 50% 
of prostate cancers through a chromosomal rearrangement, which fuses it to the upstream 
androgen receptor-dependent regulatory element controlling TMPRSS2 expression. SIM2 
overexpression is associated with changes in transcriptional control affecting other loci on 
chromosome 21 [34,35]. Target genes for MYC and ERG have been extensively explored in 
clinical and cell-line datasets using expression array profiling with targeted knockdown and 
overexpression in prostate cancer cells. These approaches have linked MYC to processes 
including ribosome biogenesis and splicing and ERG to cell motility and migration, 
respectively [36-38]. Whilst the 33 genes did not include significant number of established 
MYC target genes, several reported ERG target were present including B3GAT1, 
phospholipase A1 member A (PLA1A) and collagen, type IX, alpha 2 (COL9A2) [39]. In 
addition, there were a number of direct AR targets including UAP1 and GCNT [30,40]. 
Importantly, whilst the AR is the principal transcription factor driving all stages of prostate 
cancer development, its target genes cannot be easily inferred by coexpression with the AR in 
contrast to ERG relative to ERG target genes. Target genes for HOXC6, SIM2 and DLX1 are 
less well defined in prostate cancers but given the presence of ERG and AR target genes 
within this geneset it is highly likely that they also contribute, being transcription factors, to 
the expression of some of these genes. A more systematic understanding of the interplay 
between these transcription factors and dependent gene networks will emerge in future 
studies. This will require targeting the expression of the transcription factors in experimental 
model systems and profiling concomitant changes in transcription factor recruitment, 
chromatin architecture and gene expression. 
In the interim, however, it was possible to infer co-dependency based on co-clustering of 
genes in clinical samples. We did so in two additional datasets, an exon-array dataset 
generated by Taylor et al. and a transcriptomic dataset generated for prostate cancer through 
high-throughput sequencing by the The Cancer Genome Atlas (TCGA) (Figure 3). In both 
datasets, we were able to firstly reconfirm the ability of these 33 genes to discriminate 
between localised prostate cancer and benign tissue samples (Figure 3). Secondly, ERG co-
clustered within these 33 genes with bona fide target genes such as B3GAT1 and PLA1A 
corroborating a contribution at least from ERG to this prostate cancer-specific overexpression 
signature [39]. Intriguingly, another transcription factor, DLX1, also co-clustered with ERG 
raising the possibility of a transcription factor hierarchy in which early emergence of an ERG 
gene fusion may trigger aberrant expression of other developmental transcription factors. 
Figure 3 Heatmaps confirming the clustering ability of the 33-gene signature in a 
prostate cancer exon-array dataset (Taylor et al.) and the TCGA RNA-seq dataset for 
prostate cancer (TCGA-PRAD). The 33-gene signature was applied to two independent 
datasets, A. a prostate cancer exon-array dataset (Taylor et al.), and B. TCGA RNA-seq 
dataset for prostate cancer (TCGA-PRAD). Expression values were log2 transformed, 
normalized for high level mean and variance and hierarchically clustered using Euclidian 
distance. Genes are rows and samples are columns. The colour coded bars indicate expression 
values and the clinical grouping for each sample as defined in the keys. 
Currently prostate-specific antigen (PSA)/kallikrein 3 (KLK3) is the most widely used 
protein biomarker for prostate cancer. The androgen receptor (AR) is the most significant 
transcription factor driving prostate cancer, but is also expressed at high levels in 
untransformed luminal epithelial cells and therefore is predominantly used as a transcript 
biomarker associated with metastatic disease and concomitant copy-number amplification 
[41]. Gene fusions have been detected which significantly elevate the transcript levels of ETS 
transcription factors and the most prevalent example in prostate cancer is the TMPRSS2-ERG 
fusion [33]. Detection of the fusion has been reported in biological fluids including urine 
samples [42]. 
To assess the performance of the 33-gene signature in comparison to KLK3/PSA, AR and 
ERG we interrogated an additional independent expression array dataset generated by Grasso 
et al., and consisting of benign tissue, localised prostate cancer and metastatic cases [43]. 
This dataset was generated using two different array platforms on distinct sets of samples 
(Methods section). Cysteine-rich secretory protein-3 (CRISP3) was excluded from the 
signature due to missing values in the datasets for this gene and prostate cancer antigen 3 
(PCA3) was not represented on the arrays leaving a 31-gene signature for evaluation. In the 
first phase of the signature evaluation we assessed the weighted contribution of each gene in 
the signature using a logistical regression model on a training dataset consisting of the 
samples profiled on an Agilent oligo microarray platform. We then used the samples profiled 
on a second platform, the 4x44K Agilent microarray to evaluate the performance of the 
signature and compared this to KLK3, ERG and AR. Three pairwise sample comparisons 
were undertaken - benign versus localised prostate cancer, benign versus metastatic cases and 
localised prostate cancers versus metastatic cases. Whilst all three transcripts and the 
signature discriminated between metastatic samples and benign tissue with good specificity 
and sensitivity as reflected in an area-under-the-curve (AUC) ranging from 0.83 for the AR to 
0.99 for the signature, only the signature provided an AUC of ≥ 0.95 for all three pairwise 
comparisons (Table 9). Since both the AR and KLK3 are expressed in both untransformed 
prostate cells and prostate cancer it is perhaps not surprising that neither yielded an AUC of 
>0.65 in discriminating between localised prostate cancer and benign tissue samples. By 
contrast ERG expression is driven by a cancer-associated gene fusion and the AUC was 0.81 
(Table 9). AR is amplified and overexpressed in metastatic prostate cancers and this likely 
explains the higher AUC for this marker (0.84) in discriminating metastatic cases from 
localised prostate cancers [41]. KLK3/PSA was also higher, 0.87, in this context. ERG by 
contrast whilst consistently overexpressed in the majority of localised prostate cancers is of 
variable utility as a prognostic marker according to the study cohort examined associating 
variously positively or negatively with progression and metastasis [44-46]. In our evaluation 
the AUC for ERG in discriminating localised prostate cancer from metastatic cases was 0.61, 
performing more poorly than as a discriminator of localised prostate cancer from benign 
tissue samples. The AUC differences between the markers and the signature in each pairwise 
comparison of the sample sets was also visualised in receiver operating characteristic (ROC) 
curves (Figure 4). These comparisons highlight the importance of using a multi-gene 
signature since no single gene provides robust discrimination at all stages of the disease, no 
doubt reflecting changes in the underlying biological drivers during disease progression. We 
provide in addition AUC values for each individual gene and array probe for each of the 
pairwise sample comparisons in the test set (Additional file 12: Table S10) and the validation 
set (Additional file 13: Table S11). Although beyond the scope of this paper we hope that this 
will assist in further evaluation of the signature by researchers in the field. 
Table 9 Comparison of the performance of a 31-gene signature with ERG, AR and KLK3 in discriminating between benign tissue, localised prostate cancer and 
metastatic disease 
 id agilent_probe gene auc.benign.vs.local auc.benign.vs.met auc.local.vs.met 
1 10308 A_23_P334538 KLK3 0.85625 0.578125 0.55 
2 18945 A_24_P108401 KLK3 0.5875 0.8203125 0.8375 
3 24972 A_24_P344510 KLK3 0.6875 0.8359375 0.975 
4 9045 A_23_P301414 ERG 1 0.75 0.666666666666667 
5 15382 A_23_P57323 ERG 0.76875 0.5703125 0.5875 
6 31809 A_24_P922378 ERG 0.713333333333333 0.683333333333333 0.5125 
7 1039 A_23_P113111 AR 0.51875 0.75 0.75 
8 18899 A_24_P106297 AMACR 0.98125 0.7890625 0.8 
9 5760 A_23_P1833 B3GAT1 0.80625 0.5703125 0.7375 
10 31242 A_24_P914625 BEND4 0.9 0.6875 0.675 
11 2222 A_23_P128304 BICD1 0.90625 0.776785714285714 0.542857142857143 
12 31375 A_24_P916586 BICD1 0.666666666666667 0.573333333333333 0.6 
13 38999 A_32_P472968 BICD1 0.8125 0.5625 0.825 
14 31242 A_24_P914625 BEND4 0.9 0.6875 0.675 
15 14293 A_23_P45786 COL9A2 0.84375 0.578125 0.725 
16 13511 A_23_P419760 CRISP3    
17 12893 A_23_P403466 DLX1 0.71875 0.9453125 0.8 
18 34905 A_32_P142818 DLX1 0.955555555555555 1 0.571428571428571 
19 18202 A_23_P93058 DNAH5 0.944444444444444 0.94 0.555555555555556 
20 19295 A_24_P120462 DNAH5 0.683333333333333 0.625 0.625 
21 24667 A_24_P333461 DNAH5 0.555555555555556 0.5 0.611111111111111 
22 26067 A_24_P388786 DNAH5 0.95 0.785714285714286 0.657142857142857 
23 7096 A_23_P213424 ENC1 0.725 0.9453125 0.8 
24 29137 A_24_P69095 ENC1 0.74375 0.517857142857143 0.657142857142857 
25 18033 A_23_P91081 EPCAM 0.9625 0.78125 0.575 
26 9045 A_23_P301414 ERG 1 0.75 0.666666666666667 
27 15382 A_23_P57323 ERG 0.76875 0.5703125 0.5875 
28 31809 A_24_P922378 ERG 0.713333333333333 0.683333333333333 0.5125 
29 13214 A_23_P412214 RAP1GAP2 0.727272727272727 0.563636363636364 0.666666666666667 
30 31091 A_24_P911927 RAP1GAP2 0.6 0.6 0.555555555555556 
31 18139 A_23_P9232 GCNT1 0.975 0.705357142857143 0.7 
32 5181 A_23_P16523 GDF15 0.7625 0.59375 0.675 
33 7901 A_23_P250444 GJB1 0.86875 0.6328125 0.7375 
34 26494 A_24_P404840 GJB1 0.85625 0.642857142857143 0.714285714285714 
35 11669 A_23_P370666 GLYATL1 0.73125 0.53125 0.75 
36 7727 A_23_P2344 HOXC6 0.785714285714286 0.958333333333333 0.857142857142857 
37 147 A_23_P101806 HPN 0.925 0.75 0.5125 
38 13011 A_23_P406782 HPN 0.90625 0.703125 0.8 
39 6231 A_23_P203933 ITPR2 0.84 0.761904761904762 0.942857142857143 
40 9378 A_23_P310 MARCKSL1 0.93125 0.921875 0.6625 
41 2744 A_23_P13442 MICAL2 0.716049382716049 0.62962962962963 0.518518518518518 
42 7851 A_23_P24843 MICAL2 0.8 0.5625 0.75 
43 7314 A_23_P215956 MYC 0.8125 0.7578125 0.9125 
44 20716 A_24_P178011 MYC 0.626666666666667 0.733333333333333 0.857142857142857 
45 25948 A_24_P38363 MYC 0.5 1 1 
46 3126 A_23_P139327 OR51E2 0.85 0.645833333333333 0.683333333333333 
47 22188 A_24_P235756 OR51E2 0.88125 0.5625 0.8375 
48 8971 A_23_P29816 PLA1A 0.925 0.640625 0.725 
49 23649 A_24_P294408 PLA1A 0.9625 0.580357142857143 0.885714285714286 
50 15416 A_23_P5778 RAB17 0.928571428571429 0.830357142857143 0.675 
51 7973 A_23_P251387 REPS2 0.9875 0.78125 0.8125 
52 33496 A_32_P100109 REPS2 0.94375 0.7890625 0.9625 
53 6876 A_23_P211110 SIM2 0.914285714285714 0.803571428571429 0.7375 
54 9061 A_23_P301886 SIM2 0.8 0.916666666666667 0.5 
55 15035 A_23_P52939 SLC43A1 0.925 0.671875 0.6625 
56 22855 A_24_P260443 THBS4 0.8125 0.8046875 0.9375 
57 1849 A_23_P123503 TRIB1 0.88125 0.642857142857143 0.528571428571429 
58 22636 A_24_P252497 TRIB1 0.775 0.578125 0.825 
59 4805 A_23_P160460 UAP1 0.9625 0.7265625 0.9625 
Data were downloaded from Grasso et al.,. ROC statistics were computed in an evaluation sample set having established the weighting for genes in the signature using 
logistic regression in a test sample set. We report the area under the curve (AUC) for each transcript and for the signature for each of three pairwise comparisons as generated 
using the R package ROCR. 
Figure 4 Receiver operating characteristic (ROC) curves for discrimination between 
localised prostate cancer and benign cases, metastatic and benign cases and metastatic 
and prostate cancers using a 31-gene signature (row 1), AR (row 2), ERG (row 3) and 
KLK3 (row 4). 
Conclusions 
In conclusion, in this study we have used a multi-step approach to refine gene signatures 
derived from diverse transcript detection platforms and sample types in order to arrive at a 
robust gene signature able to discriminate between PCa and benign tissue (Figure 5). This is 
the first time that this has been attempted and demonstrates that value exists in transcript 
signatures generated from amongst the earliest microarray studies right through to high-
throughput sequencing. In brief, beginning with a small expression array dataset consisting of 
13 macrodissected samples, we have been able to derive gene signatures capable of 
subclustering localised PCa and metastases in a larger microdissected and a multi-cancer 
dataset (Figure 5). This highlights that there are valuable gene transcript signatures that can 
be robust despite cellular heterogeneity in PCa and the evolution of transcript detection 
technologies. In addition, we have discovered that gene transcripts that are significantly 
overexpressed within these signatures are also overexpressed in much more recently acquired 
exon-array and sequence-based TCGA data, transcript detection platforms that were 
unavailable when the Varambally, Tomlins and Ramaswamy studies were undertaken (Figure 
5). Finally, we have evaluated the performance of these transcripts as a signature in 
discriminating between benign tissue samples, localised PCa and metastatic disease in an 
additional dataset generated by Grasso et al. ROC curves reveal that the signature exceeds the 
performance of ERG, KLK3 or the AR as a classifier. Intriguingly, one third of these genes 
are glycosylating enzymes and transcription factors. PCa is significantly driven by a 
transcription factor, the AR, but there is increasing evidence of contributions by others and of 
interplays between them and indeed our signature does not include the AR itself. However, it 
includes both established examples (MYC and ERG) but also others that have so far been less 
studied (SIM2, DLX1 and HOXC6). Mechanistically, future work will investigate this 
transcriptional co-dependency in more detail and clinically these signatures will be further 
evaluated in clinical cohorts. 
  
Figure 5 Workflow for the identification of robust gene signatures and gene sets for 
clustering prostate cancer cases. In step 1, we identified all statistically significant 
differentially expressed Affymetrix array probes in a small dataset consisting of 13 
macrodissected clinical samples encompassing localised benign prostatic hyperplasia, 
localised prostate cancer and metastatic disease (GSE3325). We then generated gene 
signatures from these based on gene coexpression at varying stringency thresholds. These 
gene signatures were then applied to two additional datasets, a microdissected dataset 
(Tomlins et al.) and a multi-tissue site cancer and metastatic dataset (Ramaswamy et al.). A 
large number of the coexpression gene signatures clustered localised prostate cancers from 
metastatic disease and prostate metastases from metastases at other organ sites. The most 
compact gene signature able to do so consisted of 71 genes and we assessed its expression 
pattern in two additional datasets, an exon-array dataset (Taylor et al.) and in a RNA-
sequenced dataset (TCGA-PRAD). Few of the genes in the significant coexpression gene 
signatures were overexpressed genes in localised prostate cancers. In the second phase of the 
study, we abstracted all of the overexpressed genes and refined this down to a set of 33 genes 
based on significant overexpression in additional publicly available prostate cancer 
microarray datasets housed within the Oncomine database. These genes also effectively 
clustered benign versus cancer cases in an exon-array dataset (Taylor et al.) an expression 
microarray dataset (Grasso et al.) and a RNA-sequenced dataset (TCGA-PRAD). In 
conclusion, it is possible to generate gene classifiers of clinical prostate cancer from a small 
dataset of macrodissected samples with the capacity to classify larger sequenced and 
microdissected datasets based on clinical characteristics. 
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